Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: Case reports and literature review

Allergic bronchopulmonary aspergillosis (ABPA) may affect from 1% to 15% of patients with cystic fibrosis (CF).1 This disease results from hypersensitivity to Aspergillus antigens, and afflicted patients may present with airway inflammation, bronchiectasis, and bronchoconstriction. Corticosteroids are the acknowledged first-line therapy for this condition. Itraconazole is often added to therapy if there is a slow or poor response to corticosteroids.